Trials / Completed
CompletedNCT04521023
A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
A Randomized, Double-blind, Non-inferiority, Multi-center, Phase 4 Trial to Evaluate the Blood Pressure Lowering Effect of a Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cantabell Tab | Patients assigned to experimental group are treated with Cantabell Tab |
| DRUG | Candemore Plus Tab | Patients assigned to experimental group are treated with Candemore Plus Tab |
Timeline
- Start date
- 2017-09-20
- Primary completion
- 2020-01-28
- Completion
- 2020-06-03
- First posted
- 2020-08-20
- Last updated
- 2020-08-20
Locations
14 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04521023. Inclusion in this directory is not an endorsement.